![](https://investorshub.advfn.com/uicon/656161.png?cb=1539161798)
Sunday, March 03, 2019 10:32:22 AM
This is just IMO and general breakdown and my own thoughts, so please do your own DD!
A/S 3000,000,000.00 no change
O/S: went from 949.333,993 (2/2/19) to
991,150,917 (3/3/19) so an increase of 41,816,924
Call it 42 Million increase= $455,804 Proceeds at a SP of $0.0109
Last month this was $856,000 when it rose by 79 million O/S on 2/2/19
Since 9/2019 we saw 79 million and now 42 million=121 million shares added*** (see below how this comes into play for my math)
I still wait for a Float update** it has not budged for months
Float is still
525,079,355
CMTH/Tim Warbington own 79 million shares (99% public and not restricted-important protective factor for me. Actually TW holds 3 Million Preferred shares)
I am pleased this O/S has not eclipsed 1.1 B shares. I never want it to get to 1.7B- Investors understand why this is important.
Recall the rise in our O/S last spring when we also saw the gest run to 0.07!
I posted this line back in the fall and again in Feb 2019 with this as my personal strict number between 1.1 Billion and absolutely never want it over 1.7 Billion---this is critical for me.
OTCQB requirement of a SP = or > than $0.01 is still a factor!
Keeping a tight Float after all this is key for me as well-DD this my friends.
Insider selling for the past 14 months is ZERO. NONE, NO INSIDER SELLING
Insider selling has NOT taken place since 8/2017-it has instead been all buying, so I will stay in cash and follow the money!
4/11/2018 buys (acquisitions) direct Acquisition (Non Open Market) @ $0.0138 9,855,290 Shares to T.W.
4/11/2018 buys (acquisitions) indirect Acquisition (Non Open Market) @ $0.0138 9,855,290 Shares to T.W.
10/17/2018 buys (acquisitions) direct Acquisition (Non Open Market) @ $0.0225 4,444,444 Shares to T.W.
10/17/2018 buys (acquisitions) indirect Acquisition (Non Open Market) @ $0.0225 4,444,444 Shares to T.W.
Note conversion and warrants seems, IMO, to be responsible for the O/S increase.
***Outstanding Warrants: We need to get an exact number/value, but I think is 256 Million as of 9/2018,
Institutional notes less than 154 Million
Inst. Investor 154 Million + 256 Million= 410 Million total debt (Estimate) as of 9/2018.
Now take 410 Million-121 Million= 289 Million shares total remaining debt.***
So the increase of 79 as of 2/2/19 and now another 42 Million as of 3/3/19 Million O/S came from a combination of Institutional Investors and/or warrants converting. IMO!
it is what it is!
For us to hit a Market cap of $50 million or $75 million, we need the O/S to stay between what it is and less that 1.1 Billion shares at 0.05-0.065 SP-roughly!
In Biotech world average of $50 million in market cap is typical
Some are asking (Good question really): Could CMTH be buying back shares?
If you factor all debts paid by cashless conversion or buy backs with CMTH turning around and selling them publicly, then I can see a marked % return to CMTH (say 200%-700%). It all depend on how much has been exercised or converted and if any buy-backs have already taken place.
**We will see how things unfold from here to May 2019. That is when I will do a follow up on this post if needed.
My research and my opinion. My opinions is not a recommendation to buy or sell a security. Your decision whether or not to make a purchase should be based on your own due diligence.
Recent CELZ News
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM